Septerna, Inc. 8-K

What Happened

• On March 1, 2026 Septerna (SEPN) announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, and on March 2 held a conference call/webcast to discuss the data and Phase 2 plan.
• The Phase 1 trial was randomized, double-blind and placebo-controlled in healthy volunteers and evaluated single-ascending dose, multiple-ascending dose and food-effect cohorts to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD).

Key Details

• Safety/tolerability: adverse event profile comparable to placebo; no severe or serious adverse events; no clinically meaningful lab or ECG abnormalities reported.
• PK: half-life ~24 hours and no clinically meaningful food effect — supports once-daily oral dosing.
• PD/target engagement: SEP-631 strongly suppressed icatibant-induced skin wheal formation (a mast cell activation test); complete inhibition at doses as low as 10 mg after a 10 µg/mL challenge; near-to-complete inhibition at 90–200 mg after a 100 µg/mL challenge.
• Development plan: Septerna intends to initiate a randomized, double-blind, placebo-controlled global Phase 2b trial in chronic spontaneous urticaria (CSU) in H2 2026 after completing ongoing long-term toxicology studies; follow-up studies planned in dermatographism and other mast cell–driven diseases (e.g., atopic dermatitis, interstitial cystitis, migraine, asthma).

Why It Matters

• The data provide clinical proof-of-mechanism that SEP-631 engages and inhibits MRGPRX2-mediated mast cell activation in humans, and the PK/safety profile supports a convenient once-daily oral regimen — key factors for patient adoption if later trials confirm benefit.
• Near-term clinical milestone: initiation of a Phase 2b CSU study in H2 2026 is contingent on successful completion of long-term toxicology; timelines and outcomes remain subject to normal clinical and regulatory risks.
• Investors should note the company’s forward-looking statements and accompanying risk disclosures in the filing — positive Phase 1 data are an important step but not a guarantee of future clinical or commercial success.